stockportfolio.pro
Stocks / BMRN vs MDGL
BMRN vs MDGL
BioMarin Pharmaceutical Inc. and Madrigal Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioMarin Pharmaceutical Inc. (BMRN) | Madrigal Pharmaceuticals, Inc. (MDGL) | |
|---|---|---|
| Market cap | $10.9B | $11.0B |
| Revenue (latest FY) | $3.22B | $958.40M |
| Net income (latest FY) | $348.90M | $-288.28M |
| Revenue growth (5y CAGR) | 11.6% | — |
| Net margin | 10.8% | -30.1% |
| Return on equity | 5.7% | -47.8% |
| P/E ratio | 40.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMRN — free Open MDGL — freeFrequently asked questions
Which is bigger, BMRN or MDGL?
Madrigal Pharmaceuticals, Inc. is larger by market capitalization — $11.0B versus $10.9B.
Which grows faster, BMRN or MDGL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.